157 related articles for article (PubMed ID: 23196794)
1. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
Ordóñez NG
Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
[TBL] [Abstract][Full Text] [Related]
2. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Ordóñez NG
Mod Pathol; 2013 Aug; 26(8):1132-43. PubMed ID: 23503645
[TBL] [Abstract][Full Text] [Related]
3. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
4. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
6. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
[TBL] [Abstract][Full Text] [Related]
7. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
Ordóñez NG
Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
[TBL] [Abstract][Full Text] [Related]
8. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
9. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
11. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
12. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
Gao FF; Krasinskas AM; Chivukula M
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
[TBL] [Abstract][Full Text] [Related]
13. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
15. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
Churg A; Naso JR
Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
[TBL] [Abstract][Full Text] [Related]
16. Melan A (A103) is not a marker of mesothelioma.
Ordóñez NG; Shen SS; Zenali M; Deavers MT
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
[TBL] [Abstract][Full Text] [Related]
17. Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Am J Clin Pathol; 2013 May; 139(5):611-9. PubMed ID: 23596113
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
19. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
20. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB; Hirsch MS
Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
